Digital Technologies in Hereditary Coagulation Disorders: A Systematic Review

This systematic review aims to comprehensively survey digital technologies used in the prevention, diagnosis, and treatment of hereditary blood coagulation disorders.

The systematic review was performed according to the PRISMA guidelines. A systematic search was conducted on PubMed on January 29, 2024. Articles were excluded if they were reviews, meta-analyses, or systematic reviews. Articles were included if they were published from January 1, 2014, onward, written in English, described an actual application of digital tools, were in the context of hereditary coagulation disorders, and involved studies or trials on humans or human data with at least three subjects.

The initial PubMed search on January 29, 2024, identified 2,843 articles, with 672 from January 1, 2014, onward. After screening, 21 articles met the exclusion and inclusion criteria. Among these, 12 focused on artificial intelligence (AI) technologies and 9 on digital applications. AI was predominantly used for diagnosis (five studies) and treatment (four studies), while digital applications were mainly used for treatment (eight studies). Most studies addressed hemophilia A, with a smaller number including hemophilia B or von Willebrand disease.

The findings reveal a lack of intervention studies in the prevention, diagnosis, and treatment. However, digital tools, including AI and digital applications, are increasingly used in managing hereditary coagulation disorders. AI enhances diagnostic accuracy and personalizes treatment, while digital applications improve patient care and engagement. Despite these advancements, study biases and design limitations indicate the need for further research to fully harness the potential of these technologies.